140 related articles for article (PubMed ID: 16871570)
1. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
[TBL] [Abstract][Full Text] [Related]
2. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.
Morishima C; Morgan TR; Everhart JE; Wright EC; Apodaca MC; Gretch DR; Shiffman ML; Everson GT; Lindsay KL; Lee WM; Lok AS; Dienstag JL; Ghany MG; Curto TM;
Hepatology; 2008 Nov; 48(5):1412-9. PubMed ID: 18816437
[TBL] [Abstract][Full Text] [Related]
3. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
[TBL] [Abstract][Full Text] [Related]
4. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
Kadam JS; Gonzalez SA; Ahmed F; Menezes A; Jacobson IM
Dig Dis Sci; 2007 Oct; 52(10):2525-30. PubMed ID: 17406826
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
[TBL] [Abstract][Full Text] [Related]
7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
8. [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
Matsuura K; Tanaka Y; Takagi K; Hiramatsu K; Kani S; Gotoh T; Wakimoto Y; Joh T; Mizokami M
Rinsho Byori; 2007 Nov; 55(11):983-8. PubMed ID: 18154028
[TBL] [Abstract][Full Text] [Related]
9. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
[TBL] [Abstract][Full Text] [Related]
10. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
[TBL] [Abstract][Full Text] [Related]
11. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
12. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F;
Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
14. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Rivero-Juárez A; Mira JA; Pérez-Camacho I; Macías J; Camacho A; Neukam K; Torre-Cisneros J; Merchante N; Pineda JA; Rivero A;
J Antimicrob Chemother; 2011 Jun; 66(6):1351-3. PubMed ID: 21415037
[TBL] [Abstract][Full Text] [Related]
15. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
Halfon P; Pénaranda G; Bourlière M; Khiri H; Masseyeff MF; Ouzan D
J Med Virol; 2006 Feb; 78(2):208-15. PubMed ID: 16372298
[TBL] [Abstract][Full Text] [Related]
16. The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
Dalgard O; Martinot-Peignoux M; Verbaan H; Bjøro K; Ring-Larsen H; Marcellin P
PLoS One; 2015; 10(8):e0120866. PubMed ID: 26317978
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
Gerotto M; Dal Pero F; Bortoletto G; Ferrari A; Pistis R; Sebastiani G; Fagiuoli S; Realdon S; Alberti A
J Hepatol; 2006 Jan; 44(1):83-7. PubMed ID: 16271794
[TBL] [Abstract][Full Text] [Related]
18. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
Matsuura K; Tanaka Y; Hasegawa I; Ohno T; Tokuda H; Kurbanov F; Sugauchi F; Nojiri S; Joh T; Mizokami M
J Clin Microbiol; 2009 Feb; 47(2):385-9. PubMed ID: 19091819
[TBL] [Abstract][Full Text] [Related]
19. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
Ferraro D; Giglio M; Bonura C; Di Marco V; Mondelli MU; Craxì A; Di Stefano R
J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
[TBL] [Abstract][Full Text] [Related]
20. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
